Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis
Authors' conclusion
PCSK9 inhibitors significantly reduced all-cause mortality and medical utilization compared to statins
Study context
- Population
- Patients with hyperlipidaemia, TriNetX database, 1 July 2015 to 31 December 2023
- Participants
- 79,194 vs 5,437,513
- Exposure
- PCSK9 inhibitors vs statins
- PCSK9 inhibitorn = 79,194
- Statinn = 5,437,513reference
- Outcome
- All-cause mortality and medical utilization (hospital inpatient services, ED visits, critical care, mechanical ventilation)
- Follow-up
- Up to 9 years
Methodological detailspropensity-score matched
- Propensity-score matched
Main finding
As reported in the abstract
PCSK9 inhibitor vs StatinAdjusted hazard ratio (95% CI)
All-cause mortality (28.3% lower risk)
0.717(0.673–0.763)
Hospital inpatient services
0.692(0.664–0.721)
ED services
0.756(0.726–0.788)
Critical care services
0.619(0.578–0.664)
Mechanical ventilation
0.537(0.484–0.596)
Observational data: associations, not effects.
Further findings
Demographic and clinical subgroups; sensitivity analyses
- Findings consistent across subgroups; sensitivity analyses supported robustness
Original publication
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis. Eur Heart J Cardiovasc Pharmacother. Published 25 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →